Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a lead-in Phase 1B Dose Escalation Portion) in Patients With Advanced or Metastatic Renal Cell Carcinoma

NCT01806064 is registered in ClinicalTrials.gov with Tracon Pharmaceuticals Inc. as lead sponsor.

NCT NCT01806064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01806064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a lead-in Phase 1B Dose Escalation Portion) in Patients With Advanced or Metastatic Renal Cell Carcinoma
Lead sponsor
Tracon Pharmaceuticals Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
March 8, 2013
Completion date
June 12, 2019
Enrollment
173 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma